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Tamoxifen is the most commonly prescribed therapy for patients
with estrogen receptor (ER)a-positive breast tumors. Tumor re-
sistance to tamoxifen remains a serious clinical problem especially
in patients with tumors that also overexpress human epidermal
growth factor receptor 2 (HER2). Current preclinical models of
HER2 overexpression fail to recapitulate the clinical spectrum of
endocrine resistance associated with HER2/ER-positive tumors.
Here, we show that ectopic expression of a clinically important
oncogenic isoform of HER2, HER2D16, which is expressed in
>30% of ER-positive breast tumors, promotes tamoxifen resis-
tance and estrogen independence of MCF-7 xenografts. MCF-7/
HER2D16 cells evade tamoxifen through upregulation of BCL-2,
whereas mediated suppression of BCL-2 expression or treatment
of MCF-7/HER2D16 cells with the BCL-2 familypharmacological
inhibitor ABT-737 restores tamoxifen sensitivity. Tamoxifen-
resistant MCF-7/HER2D16 cells upregulate BCL-2 protein levels
in response to suppressed ERa signaling mediated by estrogen
withdrawal, tamoxifen treatment or fulvestrant treatment. In ad-
dition, HER2D16 expression results in suppression of BCL-2-
targeting microRNAs miR-15a and miR-16. Reintroduction of
miR-15a/16 reduced tamoxifen-induced BCL-2 expression and
sensitized MCF-7/HER2D16 to tamoxifen. Conversely, inhibition
of miR-15a/16 in tamoxifen-sensitive cells activated BCL-2 ex-
pression and promoted tamoxifen resistance. Our results suggest
that HER2D16 expression promotes endocrine-resistant HER2/
ERa-positive breast tumors and in contrast to wild-type HER2,
preclinical models of HER2D16 overexpression recapitulate mul-
tiple phenotypes of endocrine-resistant human breast tumors. The
mechanism of HER2D16 therapeutic evasion, involving tamoxi-
fen-induced upregulation of BCL-2 and suppression of miR-15a/
16, provides a template for unique therapeutic interventions com-
bining tamoxifen with modulation of microRNAs and/or ABT-
737-mediated BCL-2 inhibition and apoptosis.
Introduction
MicroRNAs (miRNAs) are small non-coding single-stranded RNA
regulatory molecules of  22 bp that suppress gene expression by
binding the 3#-untranslated regions of target gene messenger RNAs
(mRNAs). Once bound to their target mRNA, miRNAs may repress
gene expression through enhanced degradation of the mRNA or more
commonly by inhibiting target gene translation (1). Temporal and
spatial regulations of miR expression have profound effects on normal
cellular processes, including proliferation, differentiation and apopto-
sis. In addition, proﬁling experiments have identiﬁed aberrant miR
regulation during tumorigenesis suggesting that miRNAs may play
a role in cancer as well (2). Indeed, miRNAs inﬂuence multiple stages
of breast cancer, including tumor development (3), metastasis (4) and
therapeutic evasion (5,6).
Breast cancer is the most commonly diagnosed cancer in women
and an estimated one in eight women will developbreast caner in their
lifetimes. Nearly, 70% of breast cancer patients develop tumors
expressing the estrogen receptor (ER)a and are therefore candidates
for endocrine therapy. The selective ERa modulator tamoxifen is the
most commonly prescribed endocrine therapy in the breast cancer
clinic and has recently been recommended as a preventative in indi-
viduals at high risk of developing breast cancer (7). Nevertheless,
30–40% of breast cancer patients fail adjuvant tamoxifen therapy
and nearly all patients with metastatic disease develop tamoxifen
resistance (8–10). Unfortunately, de novo and acquired tumor resis-
tance to tamoxifen therapy remains a poorly understood and serious
clinical problem.
Several clinical studies implicate tumor expression of the human
epidermal growth factor receptor 2 (HER2) receptor tyrosine kinase
as a signiﬁcant risk for tamoxifen failure. Patients with HER2-
expressing breast tumors account for approximately half of the
ERa-positive population and .70% of these patients may exhibit
de novo tamoxifen resistance (10). Furthermore, a large percentage
of HER2/ERa-positive tumors are estrogen independent and therefore
continue to grow when patients are estrogen depleted (11). Preclinical
models of HER2 overexpression have provided insights into possible
mechanisms underlying tamoxifen resistance; however, only the
occasional HER2-overexpressing ERa-positive cell line exhibits at
best partial tamoxifen resistance, and in contrast to a signiﬁcant
percentage of primary breast tumors, HER2-overexpressing ERa-
positive breast tumor cell lines remain estrogen dependent (12–17).
We have recently shown that an oncogenic isoform of HER2
(18,19), HER2D16, is clinically important and commonly coex-
pressed with HER2 in ERa-positive primary breast tumors (20).
HER2D16 harbors an in-frame deletion, which promotes constitutive
dimerization of the receptor, thereby coupling HER2D16 to unique
oncogenic signaling pathways. We have shown previously that, in
contrast to wild-type HER2, HER2D16 expression is associated with
node-positive breast cancer and trastuzumab resistance (20). Here, we
demonstrate that expression of HER2D16, but not wild-type HER2,
in ERa-positive breast tumor cells promotes estrogen-independent
growth and de novo resistance to tamoxifen therapy. We further
demonstrate that HER2D16 evades tamoxifen therapy through a novel
mechanism involving altered regulation of BCL-2, in part by modu-
lating expression of BCL-2 targeting miRNAs.
Materials and methods
Cell lines
The MCF-7 and MDA-MB-231 cell lines were purchased from American
Type Culture Collection (Manassas, VA) and cultured according to their instruc-
tions. Stable MCF-7 cell lines expressing pcDNA3, pcDNA3-HER2 or
Abbreviations: cDNA, complementary DNA; CS-MEM, charcoal stripped
minimal essential media; ER, estrogen receptor; HER2, human epidermal
growth factor receptor 2; mRNA, messenger RNA; qRT–PCR, quantitative
reverse transcription–polymerase chain reaction; SE, standard error.
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Tumor formation in nude mice
Tumor xenografts were developed by injecting 5   106 cells in a Matrigel
Basement Membrane Matrix (BD Biosciences, Bedford, MA) into 4- to
5-week-old NU/NU immune compromised female mice (Charles River Labora-
tories, Wilmington, MA) and analyzed as described elsewhere (21) with the
following modiﬁcations. The estradiol groups were implanted subcutaneous in
the scapular region with a 60 day release 0.72 mg estradiol pellet (Innovative
Research of America, Sarasota, FL) and the minus estradiol groups were im-
planted with placebo pellets during the entire experiment. Tumors were allowed
to develop for 21 days at which time mice were randomized and implanted with
a 60 day release 5 mgtamoxifen pellet (Innovative ResearchofAmerica) or a 60
day release 5 mg placebo (Innovative Research of America). Tumor volumewas
calculated every 3 days.
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay
Cell proliferation was measured as a function of metabolism by 3-(4,5-
dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide (Sigma, St Louis,
MO) assay exactly as described elsewhere (22) with the modiﬁcation that
3000 cells per well in a 96-well plate were preincubated in phenol red-free
modiﬁed Eagle’s medium supplemented with 5% charcoal-stripped fetal bo-
vine serum [charcoal stripped minimal essential media (CS-MEM)] for 48 h
and were treated with 100 pM 17-b-estradiol (Sigma) alone or in combination
with 1.0 lM 4-hydroxytamoxifen (TAM; Sigma) for 5 days. Each sample was
preparedin triplicateandthedata representthe meanandstandarderror(SE)of
at least three independent experiments. Statistically signiﬁcant differences
between data sets were determined using paired Student’s t-test.
Western blot analysis of cell lysates
Total cell lysates were prepared from  5   106 cells in a 100 mm tissue culture
dish and analyzed by western blot exactly as described elsewhere (23). Primary
antibodies used for western blot analysis included ER Ab-1 (Neomarkers,
Fremont, CA), HER2 #RB103 (Neomarkers), a-tubulin #05829 (Upstate Bio-
technology, Lake Placid, NY) and BCL-2 (Cell Signaling Technology, Danvers,
MA). Secondary antibodies were Alexa-ﬂuor 680 Conjugated Afﬁnity Puriﬁed
Anti-Rabbit or Anti-Mouse IgG (Invitrogen, Carlsbad, CA) detected using an
Odyssey Infrared Imaging System (Licor Biosciences, Lincoln, NE). Western
blot images were quantitated using the Odyssey Infrared Imaging System soft-
ware. The integrated intensity (a measure of the magnitude of the signal and the
area over which is distributed) was measured for each band. The ‘average or
median background’ methods were used to correct for noise signals.
Luciferase reporter assay
Luciferase reporter assay to measure ERa transcriptional activity in MCF-7/
Vector, MCF-7/HER2 and MCF-7/HER2D16 stable cell lines was performed
by transfecting 2   105 cells in a six-well plate with 1 lg of an estrogen-
response-element-luciferase reporter. The estrogen-response-element-luciferase
reporter was stimulated with 100 pM17-b-estradiolalone orincombinationwith
1lM4-hydroxytamoxifenor 100 nMICI 182780 (ICI;Tocris, Ellisville, MO) for
48 h. Cell lysates were prepared in 500 ll of cell culture lysis reagent (Promega,
Madison, WI) and luciferase assay was performed on 30 ll of lysate using the
luciferase assay system (Promega) in a Berthold AutoLumat Plus luminometer.
Each sample was prepared in triplicate and the data represent the mean of the
triplicate samples.
Analysis of BCL-2 mRNA by quantitative reverse transcription–polymerase
chain reaction
Each stable MCF-7 cell line was cultured in CS-MEM for 24 h and then
treated with 100 pM 17-b-estradiol alone or in combination with 1 lM
4-hydroxytamoxifen for 1, 4, 8, 12, 24 or 48 h. Total RNA was extracted
from  5   106 cells in a 100 mm tissue culture dish using PureLink Micro to
Midi Total RNA Puriﬁcation System (Invitrogen) according to manufacturer’s
instructions. First-strand complementary DNA (cDNA) was synthesized from
1 lg of total RNA using the Superscript III First-Strand Synthesis System for
reversetranscription–polymerasechainreaction(Invitrogen)exactlyasdescribed
by the manufacturer. Quantitative reverse transcription–polymerase chain reac-
tion(qRT–PCR)wasperformedwith0.2llo fcD N Ain1   SYBR-GreenMaster
Mix (IQ SYBR, Bio-Rad, Hercules, CA) with 400 nM of each oligonucleotide
primer for BCL-2 (forward 5#-TGGGATGCCTTTGTGGAACT-3# and reverse
5#-GAGACAGCCAGGAGAAATCAAAC-3#). The b-actin internal control was
analyzed by qRT–PCR as above using 400 nM of RNA b-actin Internal Stand-
ards (Ambion, Austin, TX). The qRT–PCR reaction was performed in an iQ5-
Cycler (Bio-Rad) using the following conditions: 50Cf o r2m i n ,9 5 Cf o r
10 min, followed by 40 cycles of 95C for 15 s and 60Cf o r1m i n .T h eC t
analysis for each reaction was performed using the iQ5Cycler software and
standard curves were generated to determine qRT–PCR efﬁciency. BCL-2
mRNA levels were normalized to b-actin mRNA levels using iQ5Cycler soft-
ware and the2 DDCtmethod. Eachsamplewaspreparedin triplicateand the data
represent the mean and SE of at least three independent RNA extractions. Sta-
tistically signiﬁcant differences between data sets were determined using paired
Student’s t-test.
Suppression of BCL-2 expression
Cells were transfected with BCL-2 small-interference RNA SMARTpool or Non-
speciﬁc Negative Control Pool (Upstate Biotechnology, Boston, MA) exactly as
described elsewhere (24).
Apoptosis assay
Cell death as a result of apoptosis was quantitated by measuring mononucleo-
somes and oligonucleosomes release using the Cell Death Detection ELISA
PLUS Kit (Roche, Indianapolis, IN) following the manufacturer’s instructions
using3000cells perwell culturedin a 96-welltissuecultureplate.Eachsample
was prepared in triplicate and the data represent the mean and SE of at least
three independent experiments. Statistically signiﬁcant differences between
data sets were determined using paired Student’s t-test.
Quantiﬁcation of miR-15a and miR-16
Total RNA was isolated from  5   106 cells in a 100 mm tissue culture dish
using the MirVana PARIS RNA isolation system (Ambion) according to the
manufacturer’s instructions. cDNA from mature miR-15a and miR-16 was
synthesized from 30 ng of total RNA using the TaqMan MicroRNA Reverse
Transcription Kit (Applied Biosystems, Carlsbad, CA) as described by the
manufacturer. qRT–PCR was performed on 1.0 ll of cDNA using TaqMan
MicroRNA Assay hsa-miR-15a or hsa-miR-16 probe sets (Applied Biosys-
tems) and the TaqMan Universal PCR Master Mix, No Amperase UNG
(Applied Biosystems) exactly as described by the manufacturer. For normal-
ization, a b-actin qRT–PCR reaction was performed as described above.
Suppression of BCL-2 expression with pre-miR-15a and pre-miR-16
Each cell line plated at 3000 cells per well in a 96-well tissue culture plate was
cultured for 24 h in CS-MEM and then transfected with 30 nM of the miRNA
Precursor Molecules (pre-miR) non-speciﬁc control #2, pre-miR hsa-miR-15a
or pre-miR hsa-miR-16 (Qiagen, Valencia, CA) using Hyperfect Reagent
(Qiagen) as described by the manufacturer. At 1 day posttransfection, cells
were treated with 100 pM 17-b-estradiol alone or in combination with 1.0 lM
4-hydroxytamoxifen. After 48 h, cell lysates were analyzed for BCL-2 expres-
sion by western blot or if growth assays were performed, cells were transfected
a second time with pre-miR non-speciﬁc control 2, pre-miR hsa-miR-15a or
pre-miR hsa-miR-16. The 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazo-
lium bromide growth assay was performed after an additional 72 h. Each
sample was prepared in triplicate and the data represent the mean and SE of
at least three independent experiments. Statistically signiﬁcant differences
between data sets were determined using paired Student’s t-test.
Inhibition of miR-15a and miR-16
Each cell line plated at 3000 cells per well in a 96-well tissue culture plate was
cultured for 24 h in CS-MEM and then transfected with 50 or 100 nM of
miRIDIAN miRNA inhibitor non-speciﬁc control 1, miRIDIAN miRNA in-
hibitor hsa-miR-15a or miRIDIAN miRNA inhibitor hsa-miR-16 (Dharmacon,
Lafayette, CO) using Hyperfect Reagent (Qiagen) according to the manufac-
turer’s instructions. At 1 day posttransfection, cells were treated with 100 pM
17-b-estradiol alone or in combination with 1.0 lM 4-hydroxytamoxifen and
a 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide growth as-
say was performed at 5 days posttransfection. Each sample was prepared in
triplicate and the data represent the mean and SE of at least three independent
experiments. Statistically signiﬁcant differences between data sets were
determined using paired Student’s t-test.
Results
HER2D16 expression promotes estrogen independence and tamoxifen
resistance
We have shown that .50% of HER2-positive breast tumors coexpress
the oncogenic HER2 isoform HER2D16. We further demonstrated
that HER2D16 expression is strongly associated with metastatic
breast tumors and tumor cell resistance to the HER2-targeted therapy
trastuzumab (20). These ﬁndings implicated HER2D16 as a clinically
important oncogenic event driving aggressive and therapy refractory
HER2-positive breast cancer. In the same study, we found that 26% of
HER2D16-expressing breast tumors were also ERa positive (20).
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overexpression of HER2 cannot discriminate between HER2D16 and
wild-type HER2 expression. The covert inﬂuence of HER2D16
oncogenic activity on ERa function and tumor cell response to endo-
crine therapy may explain the inability of preclinical models of wild-
type HER2 overexpression to fully recapitulate the aggressive and
variable clinical nature of HER2/ERa-positive tumors.
To determine the impact of HER2D16 expression on the biology of
ERa-positive breast tumor cells, we compared the activities of
HER2D16 and wild-type HER2 in the ERa-positive MCF-7 breast
tumor cell line. Stable expression of HER2D16 resulted in reduced
ERa levels when compared with the MCF-7/Vector and MCF-7/
HER2 cell lines (supplementary Figure S1a is available at Carcino-
genesis Online). However, equivalent levels of ERa transcriptional
activity was observed in each cell line and ERa activity was abolished
by treatment with tamoxifen or fulvestrant (supplementary Figure S1b
is available at Carcinogenesis Online). Each cell line therefore ap-
pears to retain normal regulation of ERa function by estrogen and the
two endocrine therapies tested.
We ﬁrst compared the ability of each cell line to form xenograft
tumors under different growth conditions. As expected, MCF-7/Vector
xenografts were estrogen dependent, failing to become established
in the absence of exogenous estrogen. In addition, MCF-7/Vector
tumors established in the presence of estrogen rapidly regressed when
mice were treated with tamoxifen (Figure 1a). Consistent with other
reports, we found that MCF-7/HER2 xenografts were also estrogen
dependent (17). Established MCF-7/HER2 xenografts initially re-
gressed in response to tamoxifen but then continued to slowly expand.
However, in concordance with other studies using similar HER2-
overexpressing cell lines, the ﬁnal MCF-7/HER2 tumor volume was
less than half of estrogen control xenografts (13,17) (Figure 1b).
MCF-7/HER2D16 xenografts were estrogen responsive forming rap-
idly expanding large tumors in the presence of estrogen. In contrast to
the other cell lines, MCF-7/HER2D16 tumors were estrogen indepen-
dent and in the absence of estrogen formed tumors larger than
estrogen-treated MCF-7/Vector and MCF-7/HER2 xenografts. Fur-
thermore, MCF-7/HER2D16 xenografts exhibited robust tamoxifen
resistance with only a 13% reduction in ﬁnal tumor volume when
compared with estrogen-treated MCF-7/HER2D16 xenografts (Figure
1c). Interestingly, the growth kinetics of tamoxifen-treated MCF-7/
HER2D16 xenografts were nearly identical to MCF-7/HER2D16 xen-
ografts grown in the absence of estrogen, suggesting that ERa signal-
ing has minimal impact on MCF-7/HER2D16 tumor growth.
Similar results were observed in an in vitro cell proliferation assay
where estrogen withdrawal or tamoxifen treatment signiﬁcantly re-
duced MCF-7/Vector and MCF-7/HER2 cell growth (Figure 1d) with
a 3-fold increase in cell apoptosis (Figure 1e). In contrast, tamoxifen
only marginally inhibited MCF-7/HER2D16 cells (Figure 1d) and
Fig. 1. HER2D16 expression promotes estrogen independent and tamoxifen-resistant growth. (a–c) Graphs representing xenograft tumor kinetics of at least ﬁve
nude mice per group injected with (a) MCF-7/Vector, (b) MCF-7/HER2 or (c) MCF-7/HER2D16 cells. With the exception of the E2 treatments, all mice
were primed with E2 pellets and after 21 days, mice with established tumors were left untreated or implanted with TAM pellets. (d and e) MCF-7/HER2D16 cells
are E2 independent and TAM resistant in vitro. (d and e) MCF-7/HER2D16 cells are estrogen independent and tamoxifen resistant in vitro. (d) Each cell line was
untreated or treated for 5 days with 100 pM E2 alone or in combination with 1.0 lM TAM. 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide
assay was used to quantitate cell growth. Results represent mean ± SE percent growth inhibition relative to 100 pM E2 alone. (e) Each cell line was cultured for
24 h in CS-MEM and treated for 72 h with 100 pM E2 alone or in combination with 1.0 lM TAM. Apoptosis was quantitated using a Cell Death Detection ELISA.
Results represent apoptosis relative to cells treated with 100 pM E2 alone.
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demonstrate that expression of HER2D16, but not wild-type HER2,
renders ERa-positive MCF-7 breast tumor cells estrogen independent
and tamoxifen resistant. The initial tamoxifen response and subse-
quent impaired growth of MCF-7/HER2 xenografts reported here
and elsewhere (15) suggest that wild-type HER2 has a greater impact
on acquired tamoxifen resistance than de novo tamoxifen resistance.
HER2D16-expressing MCF-7 xenografts, on the other hand, more
closely resemble the estrogen independent and de novo tamoxifen-
resistant phenotype of aggressive HER2/ERa-positive tumors com-
monly observed in the clinic (10).
Upregulation of BCL-2 in MCF-7/HER2D16 cells promotes tamoxifen
resistance
Tumor cell apoptosis plays an important role in both preclinical and
clinical responses to tamoxifen (25). The BCL-2 proto-oncogene is
a potent inhibitor of the intrinsic or mitochondrial cell death pathway
and several lines of experimental and clinical evidence indicate that
activation of the intrinsic apoptotic pathway is an important mecha-
nism of tamoxifen action (21,25). Indeed, we have shown that over-
expression of the antiapoptotic BCL-2 proto-oncogene converts
tamoxifen-sensitive breast tumor cells to a tamoxifen-resistant phe-
notype (21). Interestingly, BCL-2 is an estrogen-responsive gene and
tamoxifen suppresses BCL-2 expression in tamoxifen-sensitive breast
tumor cells (25).
We determined the inﬂuence of endogenous BCL-2 expression on
theresponseoftamoxifen-resistantandtamoxifen-sensitiveMCF-7cell
lines. Consistent with previous observations, estrogen stimulated BCL-
2 mRNA expression by several fold in each MCF-7 cell line tested (26)
and as expected, the addition of tamoxifen suppressed BCL-2 expres-
sion to below basal levels (Figure 2a). Despite tamoxifen-induced
suppression of BCL-2 mRNA in each cell line tested, the tamoxifen-
resistant MCF-7/HER2D16 cell line accumulated signiﬁcant levels
BCL-2 protein during the 72 h tamoxifen treatment (Figure 2b). To
our knowledge, this is the ﬁrst demonstration of tamoxifen-induced
upregulation of BCL-2 protein in breast tumor cells. Interestingly,
a similar upregulation of BCL-2 protein was observed in MCF-7/
HER2D16 cells treated with the pure antiestrogen fulvestrant (ICI
182780) and during estrogen withdrawal (Figure 2c). These results
suggest that HER2D16-speciﬁc upregulation of BCL-2 may occur in
response to suppressed ERa activity.
We next determined if BCL-2 activity promotes tamoxifen resis-
tance of MCF-7/HER2D16 cells using an RNAi approach and phar-
macological inhibition. Signiﬁcantly, treatment of MCF-7/HER2D16
cells with BCL-2 targeting small-interference RNA reduced tamoxi-
fen-induced BCL-2 expression (Figure 3a) and sensitized MCF-7/
HER2D16 cells to tamoxifen (Figure 3b) with increased cellular ap-
optosis (Figure 3c). As expected, BCL-2 RNAi failed to signiﬁcantly
increase growth inhibition or apoptosis in the tamoxifen-sensitive
MCF-7/Vector and MCF-7/HER2 cell lines (Figure 3b and c).
ABT-737 (Abbott Laboratories, Abbott Park, IL) is a small molecule
BH3 mimetic, which binds to and inhibits antiapoptotic members of the
BCL-2 family, including BCL-2 itself (27). An oral version of ABT-737
is currently in clinical trials for the treatment of a broad spectrum of
Fig. 2. BCL-2 upregulation mediates tamoxifen resistance of MCF-7/HER2D16 cells. (a) Quantitation of estrogen-induced BCL-2 mRNA expression. Each cell
line was treated the indicated time with 100 pM E2 alone or in combination with 1.0 lM TAM. Each RNA sample was analyzed in triplicate, normalized to
a b-actin internal control and BCL-2 mRNA expression is represented relative to the untreated MCF-7/Vector. (b) BCL-2 protein is upregulated in tamoxifen-
treated MCF-7/HER2D16 cells. Each cell line was cultured for 48 h in phenol red-free modiﬁed Eagle’s medium containing 5% charcoal-stripped fetal bovine
serum and then treated as above and cell lysates were analyzed by western blot for BCL-2 expression 24, 48 and 72 h after treatment. (c) Inactivation of ERa
signaling induces BCL-2 protein upregulation in MCF-7/HER2D16 cells. The MCF-7/HER2D16 cell line was cultured for 48 h in and left untreated (-E2) or
treated with 1.0 lM TAM or 100 nM ICI 18278 (ICI) for the indicated time. Cell lysates were prepared and analyzed by western blot for BCL-2 expression. In all
cases, western blot analysis of a-tubulin was included as a loading control and images were quantitated using the Odyssey Infrared Imaging System software.
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sistance of breast tumors has not been investigated. Treatment of cell
lines with physiological levels of ABT-737 increased tamoxifen activity
in MCF-7/Vector cells and sensitized MCF-7/HER2D16 cells to tamox-
ifen with a dramatic increase in growth inhibition (Figure 3d). Taken
together, these results indicate that HER2D16 promotes tamoxifen
resistance through a unique mechanism involving tamoxifen-induced
upregulation of BCL-2 protein expression. Our ﬁndings have important
clinical implications and may explain why quantitation of pretreatment
or basal levels of tumor BCL-2 expression fails to predict tamoxifen
response (25).
HER2D16 suppresses expression of BCL-2 targeting miR-15a and
miR-16
Despite the fact that tamoxifen suppresses BCL-2 mRNA expression
in each cell line examined, a dramatic upregulation of BCL-2 protein
in the MCF-7/HER2D16 cells was observed and our data indicate
that the enhanced BCL-2 expression levels directly contributes to
tamoxifen resistance. We next explored the molecular mechanisms
underlying altered BCL-2 expression in the tamoxifen-resistant MCF-
7/HER2D16 cells. Each cell line had similar rates of BCL-2 mRNA
decay (supplementary Figure S2a is available at Carcinogenesis On-
line) ruling out increased BCL-2 mRNA stability as a possible mech-
anism of BCL-2 upregulation. Another possible mechanism of
upregulated BCL-2 expression is the involvement of miRNAs, which
have been shown to alter gene expression, independent of mRNA
levels, through the suppression of target gene translation (1). We
therefore investigated the potential role of BCL-2 targeting miR-
15a and miR-16 (29) in the suppression of BCL-2 translation. Signif-
icantly, basal levels of both miR-15a and miR-16 were similar in the
tamoxifen-sensitive MCF-7/Vector and MCF-7/HER2 cells (Figure
4a) and tamoxifen failed to enhance BCL-2 expression in these cell
lines. In contrast, the levels of miR-15a and miR-16 in the tamoxifen
resistant and BCL-2-expressing MCF-7/HER2D16 cell line were
Fig. 3. Suppression of BCL-2 restores tamoxifen sensitivity. (a) RNAi-mediated suppression of BCL-2 expression. The MCF-7/HER2D16 cell line was cultured
for 24 h in phenol red-free modiﬁed Eagle’s medium containing 5% charcoal-stripped fetal bovine serum and treated with non-speciﬁc control or BCL-2-speciﬁc
RNAi. Immediately after transfection, each sample was treated with 1.0 lM 4-hydroxytamoxifen for an additional 48 h. Cell lysates were analyzed for BCL-2
expression by western blot. Western blot analysis of a-tubulin was included as a loading control and images were quantitated using the Odyssey Infrared Imaging
Systemsoftware.(b) SuppressionofBCL-2restorestamoxifensensitivityto MCF-7/HER2D16cells.Eachcell linewastreated withnon-speciﬁc controlorBCL-2
RNAi. Each sample was treated with 100 pM E2 alone or in combination with 1.0 lM TAM for 72 h. 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium
bromideassaywasused to quantitatecell growth.Resultsrepresentmean ±SEpercentgrowth inhibitionrelative to100 pM E2alone.Asterisksindicatesigniﬁcant
difference by paired Student’s t-test (P 5 0.007). (c) Suppression of BCL-2 sensitizes MCF-7/HER2D16 cells to tamoxifen-induced apoptosis. Each cell line was
treated as above and apoptosis was quantitated using a Cell Death Detection ELISA. Results represent mean ± SE apoptosis relative to MCF-7/Vector treated with
100 pM E2 alone of three independent experiments of samples prepared in triplicate. Asterisks indicate samples with signiﬁcant differences by paired Student’s
t-test (P , 0.001). (d) The BCL-2 inhibitor ABT-737 sensitizes MCF-7/HER2D16 cells to tamoxifen. Each cell line was cultured for 48 h in CS-MEM and then
treated with 100 pM E2, 100 pM E2 and 1.0 lM TAM alone or in combination with 5 lM of the BCL-2 family inhibitor ABT-737 for 5 days. Results represent
mean percent growth inhibition of triplicate samples relative to cells treated with 100 pM E2 alone.
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15a and miR-16 levels by only 40% was sufﬁcient to relieve repression
of BCL-2 protein expression (29). Expression of miR-15a/16 was not
signiﬁcantlyaltered whencells were treated withestrogen or tamoxifen
(Figure 4b). In addition, HER2D16 expression failed to impact miR-
15a/16 in the ERa-negative MDA-MB-231 cell line, which expressed
lower levels of miR-15a/16 when compared with MCF-7 cells and
lacked tamoxifen-induced expression of BCL-2 (supplementary Figure
S2b and c is available at Carcinogenesis Online).
Reestablished miR-15a/16 expression sensitizes MCF-7/HER2D16
cells to tamoxifen
We next determined if reintroduction of miR-15a and/or miR-16 was
sufﬁcient to suppress BCL-2 expression and sensitize MCF-7/
HER2D16 cells to tamoxifen treatment. Transfection of MCF-7/
HER2D16 cells with pre-miR-15a, pre-miR-16 or the combination
of both resulted in suppression of BCL-2 expression by 43, 57 and
49%, respectively (Figure 5a). The miR-15a and/or miR-16-treated
MCF-7/HER2D16cellsweresensitizedtotamoxifenwithasigniﬁcant
increase in growth inhibition observed in cells treated with pre-
miR-16 and the pre-miR-15a/16 combination (Figure 5b). The levels
of growth inhibition were in concordance with the levels of BCL-2
suppression induced by the different pre-miR-15a and pre-miR-16
combinations (Figure 5a and b). A signiﬁcant increase in MCF-7/
HER2D16 cell apoptosis in response to tamoxifen was also observed
when cells were treated with the different pre-miR combinations
(Figure 5c). These results suggest that HER2D16 employs a novel
mechanism of tamoxifen resistance by suppressing expression of
BCL-2 regulating miRNAs.
Suppressed miR-15a/16 expression promotes tamoxifen resistance
Based upon the ability of reestablished miR-15a and miR-16 expres-
sion to suppress BCL-2 expression and sensitize MCF-7/HER2D16
cells to tamoxifen, we next performed the converse experiment and
determined if suppression of miR-15a or miR-16 expression would
convert tamoxifen-sensitive MCF-7/Vector and MCF-7/HER2 cell
lines to a tamoxifen-resistant phenotype. Pretreatment of MCF-7/
Vector and MCF-7/HER2 cells with inhibitors of miR-15a or miR-
16 enhanced BCL-2 expression in the MCF-7/Vector and MCF-7/
HER2 cell lines (Figure 6a). Although antisense inhibition of miR
Fig. 4. HER2D16 expression suppresses miR-15a and miR-16. (a)
Expression of miR-15a and miR-16 is suppressed in MCF-7/HER2D16 cells.
Total RNAwas extracted and analyzed for miR-15a or miR-16 expression by
qRT–PCR. Results from three independent RNA extractions are represented
as mean ± SE expression relative to b-actin. The lower levels of miR-15a and
miR-16 expression in the MCF-7/HER2D16 cells failed to reach signiﬁcance
(paired Student’s t-test; P 5 0.07 and P 5 0.08, respectively). (b) Expression
of miR-15a and miR-16 is not altered by estrogen or tamoxifen. Each cell
line was cultured for 48 h in phenol red-free modiﬁed Eagle;s medium
containing5%charcoal-stripped fetal bovine serumand thenleft untreatedor
treated for 16 h with 100 pM E2 alone or in combination with 1.0 lM TAM.
Three independent total RNA extractions from each cell line were analyzed
in triplicate for miR-15a and miR-16 expression by qRT–PCR. Results were
normalized to b-actin and represented as mean ± SE expression relative to
untreated MCF-7/Vector cells. Differences failed to obtain signiﬁcance as
determined by paired Student’s t-test.
Fig. 5. Expression of pre-miR-15a/16 sensitizes MCF-7/HER2D16 cells to
tamoxifen. (a) Pre-miR-15a and/or pre-miR-16 suppresses BCL-2
expression. The MCF-7/HER2D16 cell line was untreated or treated with
30 nM of the indicated pre-miR and treated with 100 pM E2 and 1.0 lM
TAM for 48 h. Cell lysates were analyzed by western blot and BCL-2
expression relative to the untreated control was quantitated by densitometry.
(b and c) Pre-miR-15a and/or pre-miR-16 sensitizes MCF-7/HER2D16 cells
to tamoxifen. The MCF-7/HER2D16 cell line was transfected with pre-miRs
as above, treated with 100 pM E2 alone or in combination with 1.0 lMT A M
for 72 h. (b) 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide
assay was used to quantitate cell growth or (c) apoptosis was quantitated
using a Cell Death Detection ELISA. Data represents mean ± SE of three
independent experiments performed with triplicate samples relative to mock
and E2/TAM-treated cells. Asterisks indicate samples with signiﬁcant
differences as determined by paired Student’s t-test (b, P , 0.001; c,
pre-miR-15a, P 5 0.029; pre-miR16, P 5 0.004; pre-miR15a/16, P 5 0.017).
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anti-miR-16 in the MCF-7/Vector and MCF-7/HER2 cell lines re-
sulted in a signiﬁcant increase in tamoxifen resistance (Figure 6b).
Theincreaseintamoxifenresistancewasaccompaniedbyasigniﬁcant
reduction in apoptosis in MCF-7/Vector and MCF-7/HER2 cells trea-
ted with anti-miR-15a or anti-miR-16 (Figure 6c). These results
further implicate the BCL-2 targeting miR-15a/16 as important reg-
ulators of BCL-2 expression and tamoxifen response and suggest that
oncogene suppression of miR-15a and/or miR-16 may represent an
important mechanism of tamoxifen resistance.
Discussion
Deciphering the mechanistic basis of tumor resistance to tamoxifen
therapy continues to pose a signiﬁcant challenge to both researchers
and clinicians. Clinically, HER2 expression has been implicated as
a possible mechanism of tamoxifen resistance (10); however, preclin-
ical models of HER2 overexpression fail to fully recapitulate the
phenotypes of refractory HER2- and ERa-positive tumors. We re-
cently identiﬁed an oncogenic isoform of HER2, HER2D16, coex-
pressed in a signiﬁcant percentage of HER2- and ERa-positive breast
tumors (20). Here, we show that similar to clinical observations,
HER2D16-expressing xenografts are both tamoxifen resistant and
estrogen independent, whereas consistent with other reports, HER2-
expressing xenografts display only partial acquired tamoxifen resis-
tance and remain estrogen dependent (12–17). Our data indicates that
HER2D16 xenografts phenocopy tamoxifen resistance observed clin-
ically; therefore, this preclinical model may provide unique insights
into the molecular complexity of endocrine-resistant HER2- and
ERa-positive tumors.
Although tamoxifen induces growth arrest of sensitive tumor cells,
apoptosis has emerged as an important mechanism of tamoxifen action
(21,25) and tumor cell evasion of apoptosis contributes to tamoxifen
resistance (21). In this communication and elsewhere, we have shown
that tamoxifen-sensitive xenograft tumors decrease in size following
tamoxifen treatment further supporting cell death as an important
mechanism of tamoxifen action (21). In contrast, tamoxifen-
resistant HER2D16-expressing cells evade apoptosis in part through
upregulation of antiapoptotic BCL-2. Indeed, suppression of BCL-2
expression by RNAi or treatment with the pharmacological inhibitor
of antiapoptotic BCL-2 family members, ABT-737, sensitized
HER2D16-expressing cells to tamoxifen with increased apoptosis.
Importantly, HER2D16 employs a novel mechanism to upregulate
BCL-2 protein levels in response to suppression of ERa activity.
Consistent with other reports, we found that BCL-2 transcription is
suppressed in response to tamoxifen (30,31). However, when ERa
activity is disengaged by tamoxifen or fulvestrant treatment or estro-
gen withdrawal, we observe a dramatic upregulation of BCL-2 protein
in HER2D16-expressing MCF-7 cells. Our preclinical results may
explain the absence of clinical evidence implicating tumor expression
of BCL-2 in tamoxifen resistance. Similar to our preclinical models,
pretreatment levels of BCL-2 are similar in both tamoxifen-sensitive
and tamoxifen-resistant tumors (32,33). However, also in concor-
dancewith our ﬁndings, high levels of BCL-2 expression are observed
in tamoxifen refractory tumors (34) raising the possibility that BCL-2
expression is treatment induced in this clinical setting. Thus, preclin-
ical and clinical evidence suggests that measuring tumor cell BCL-2
Fig. 6. Suppressed miR-15a/16 expression promotes tamoxifen resistance. (a) Inhibition of miR-15a/16 results in enhanced BCL-2 expression. Each cell linewas
treated with 50 nM of the indicated miR inhibitor for 48 h and BCL-2 expression was analyzed by western blot. Analysis of a-tubulin was included as a loading
control and images were quantitated using the Odyssey Infrared Imaging System software. (b and c) Suppression of miR-15a/16 promotes tamoxifen resistance.
Each cell linewas untreated or treated with the indicated anti-miR and treated with 100 pM E2 alone or in combination with 1.0 lM TAM for ﬁve days. (b) 3-(4,5-
dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide assay was used to quantitate cell growth and (c) apoptosis was quantitated using a Cell Death Detection
ELISA. Data are represented as mean ± SE of three independent experiments performed with triplicate samples relative to mock anti-miR and E2/TAM-treated
MCF-7/Vector cells. Asterisks indicate samples with signiﬁcant differences as determined by paired Student’s t-test (P , 0.008).
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positive tumors, may strengthen the clinical signiﬁcance of BCL-2
as a marker of resistance.
We investigated the molecular basis of enhanced BCL-2 protein
expression in HER2D16-expressing cells and found a potential role
for miRNAs. BCL-2 translation is repressed by binding of miR-15a or
miR-16 to a seed sequence in BCL-2 mRNA 3#-untranslated regions,
and loss of miR-15a/16 in several cancer cell lines and tumors is
associated with BCL-2 upregulation (29,35,36) and resistance to ther-
apy (36). We found that miR-15a/16 modulate BCL-2 expression in
breast tumor cells and contribute to tamoxifen resistance. For example,
BCL-2isupregulatedinHER2D16expressingtamoxifen-resistantcells
where levels of miR-15a/16 were reduced compared with tamoxifen-
sensitive cell lines. Reintroduction of miR-15a/16 suppressed BCL-2
expression and sensitized resistant cells to tamoxifen. Conversely,
suppression of miR-15a/16 resulted in upregulation of BCL-2 and
converted sensitive cells to a tamoxifen-resistant phenotype.
We failed to detect altered miR-15a/16 expression in response to
disrupted ERa signaling suggesting that additional mechanisms may
contributetothe increased expression ofBCL-2 inHER2D16 express-
ing cells. Bioinformatic algorithms predict that the 3#-untranslated
regions of BCL-2 is targeted by .40 miRNAs broadly conserved
among vertebrates. Of particular interest, for our studies, is the
BCL-2 targeting miR-21 (37,38), which appears to be upregulated
in response to endocrine therapy, thereby suppressing BCL-2 expres-
sion in therapeutic-sensitive MCF-7 cells (38). Similar to our obser-
vations of miR-15a/16, however, expression of miR-21 is suppressed
in tamoxifen-resistant MCF-7 cells (5) and, although not formally
investigated, one would predict that BCL-2 expression would be up-
regulated in these resistant cells. We could not conﬁrm a direct role
for miR-21 in HER2D16-induced endocrine resistance (D.Cittelly and
F.Jones, unpublished data). Nevertheless, altered regulation of BCL-
2-targeting miRNAs has emerged as a potential mechanism of endo-
crine resistance worthy of clinical validation. Additional miRNA
pathways involving targets other than BCL-2 have also been shown
to inﬂuence tamoxifen response of breast tumor cells (5,6) further
underscoring the potential complexity of miRNA regulation of mul-
tiple non-overlapping endocrine resistance pathways.
In summary, we show that the clinically important HER2 isoform,
HER2D16, promotes estrogen independent growth of ERa-positive
breast tumor cells and cooperates with BCL-2 to evade tamoxifen
therapy. We further show that HER2D16-expressing cells upregulate
BCL-2 expression in response to tamoxifen, in part, through a unique
mechanism involving suppression of the BCL-2 targeting miR-15a/
16. The covert clinical inﬂuence of HER2D16 expression in HER2/
ERa-positive tumors may explain the inability of wild-type HER2
preclinical models to fully recapitulate the aggressive and variable
clinical nature of HER2/ERa-positive breast tumors (12,13,15–17).
Breast tumor expression analysis of both HER2D16 and miR-15a/16
may provide improved markers of tamoxifen resistance and novel
targets for therapeutic intervention. One intriguing possibility based
upon our preclinical data involves combining endocrine therapy with
the BCL-2 family pharmacological inhibitor ABT-737 for the treat-
ment of women presenting with HER2D16/ERa-positive tumors and
therefore predicted to be at increased risk of endocrine therapy failure.
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Supplementary Figures S1 and S2 can be found at http://carcin
.oxfordjournals.org/
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